ConvaTec Group (LON:CTEC) Given Outperform Rating at Citigroup

ConvaTec Group (LON:CTEC)‘s stock had its “outperform” rating reaffirmed by analysts at Citigroup in a research report issued on Thursday, MarketBeat Ratings reports. They presently have a GBX 315 price target on the stock. Citigroup’s price objective suggests a potential upside of 26.10% from the stock’s previous close.

Several other analysts have also recently commented on CTEC. UBS Group reiterated a “buy” rating and issued a GBX 375 price objective on shares of ConvaTec Group in a research note on Friday, November 7th. Berenberg Bank boosted their price target on ConvaTec Group from GBX 330 to GBX 340 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th. Finally, Peel Hunt reiterated an “add” rating and set a GBX 270 target price on shares of ConvaTec Group in a research report on Thursday, November 13th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, ConvaTec Group has a consensus rating of “Buy” and a consensus target price of GBX 319.57.

ConvaTec Group Price Performance

CTEC stock traded up GBX 6.60 on Thursday, reaching GBX 249.80. 8,050,717 shares of the company’s stock were exchanged, compared to its average volume of 18,153,898. The stock has a fifty day moving average of GBX 235.62 and a 200-day moving average of GBX 236.53. The firm has a market cap of £4.87 billion, a PE ratio of 23.57, a P/E/G ratio of 0.93 and a beta of 0.73. The company has a quick ratio of 0.96, a current ratio of 1.53 and a debt-to-equity ratio of 106.19. ConvaTec Group has a twelve month low of GBX 209.40 and a twelve month high of GBX 311.20.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.